Perrigo Company plc, PRGO is in the exchange NYSE and its industry is Drug Related Products in the sector of Healthcare. Based in Ireland, Perrigo Company plc, PRGO has a market cap of 12299.71. Since its IPO date on the 12/17/1991, Perrigo Company plc, PRGO performance year to date is -40.36%. Today Perrigo Company plc, PRGO has gained 0.15%, with a current price of 85.92.
Ownership of the company is 0.10% for insider ownership while institutional ownership is 73.30%. The management of the company have seen the company have a payout ratio of *TBA. Return of assets are at *TBA, with return on investment at 0.60%.
In terms of debt levels and profit levels, Perrigo Company plc, PRGO is seeing a long-term debt/equity of 0.65. While Total debt/equity is 0.68. With a profit margin of *TBA, this is combined with a gross margin of 38.20%, and operating margin of *TBA. Perrigo Company plc ability to meet debt levels, with a current ratio of 1.7, while the quick ratio is 1.1.
For the last year Perrigo Company plc, PRGO has seen a EPS growth of -95.80%. A performance for the year of -42.23%. The 52-week high is -43.27%, and the 52-week low is 7.95%. The average volume for Perrigo Company plc, PRGO is 133231.
With a target price of 103.5, can Perrigo Company plc, PRGO reach this target? Looking at the value indicators of Perrigo Company plc, PRGO. Perrigo Company plc has a P/E of *TBA and a forward P/E of 11.33. Perhaps the more useful indicator than P/E, is PEG which has a value of *TBA. Perrigo Company plc also has a P/S and a P/B of 2.18 and 1.42 respectively. For P/cash, Perrigo Company plc has a value of *TBA, while it is *TBA for P/free cash flow.
At the current price of 85.92, Perrigo Company plc has a dividend yield of 0.68%. We see a return on equity of *TBA.
Looking more long-term Perrigo Company plc, is projected to get an EPS growth for the next five years of 6.33%. In the short-term an EPS growth of 8.50% in the next year is forecasted. This is after a EPS growth of -95.80% for this year and for the last five years a -59.80% growth has been seen.